Table 1.
Patient characteristics. All percentages are based on the number of patients (n = 39).
| Variables | Number (%) or Median (IQR; Range) |
|---|---|
| RE procedures | 42 (100) |
| Age [years] | 61 (IQR, 56–69; range, 32–82) |
| Female/male sex | 26/13 (100) |
| ECOG performance status | |
| - 0 | 19 (49) |
| - 1 | 16 (41) |
| - 2 | 4 (10) |
| Baseline laboratory parameters | |
| - Total bilirubin [mg/dL] | 0.5 (IQR, 0.4–0.7; range, 0.1–1.4) |
| - AST [U/L] - ALT [U/L] |
41 (IQR, 35–65; range, 25–394) 25 (IQR, 17–38; range, 12–128) |
| - AST/ALT ratio | 1.8 (IQR, 1.4–2.5; range, 0.73–5.13 |
| - GGT [U/L] - Albumin [g/L] - INR - Ammonia [µmol/L] - CA19-9 [U/mL] |
222 (IQR, 91–383; range, 24–1210) 40.6 (IQR, 37.2–42.9; range, 31–47) 1.06 (IQR, 1–1.1; range, 0.92–1.9) 36.2 (IQR, 28.9–52.6; range, 20.2–83.1) 72 (IQR, 8.7–259.8; range, 1.9–36249) |
| Presence of | |
| - Extrahepatic tumor manifestation | 20 (51) |
| - Thrombosis of the portal vein | 8 (21) |
| - Ascites - Sequential RE |
6 (15) 3 (8) |
| Baseline hepatic tumor burden | |
| - unilobar | 20 (51) |
| - bilobar - Liver volume [mL] - Hepatic tumor burden [mL] - Total tumor burden [%] ≤25% 26–50% >50% |
19 (49) 1804 (IQR, 1477–2229; range, 947–3560) 316 (IQR, 75–589; range, 22–1838) 14.5 (IQR, 4.5–29.9; range, 1.9–51.6) 27 (69) 10 (256) 2 (5) |
| Hepatopulmonary shunt [%] | 9.8 (IQR, 6.6–12.3; range, 2.6–18.7) |
| Prior treatment | 36 (92) |
| - Chemotherapy - Hepatic surgery - Local hepatic therapy |
29 (74) 21 (54) 8 (21) |
| - Intraarterial therapy | 3 (8) |